ONCY vs. LPTX, MIST, ASRT, TPST, ACRS, LTRN, ETON, HOOK, CUE, and CARM
Should you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Leap Therapeutics (LPTX), Milestone Pharmaceuticals (MIST), Assertio (ASRT), Tempest Therapeutics (TPST), Aclaris Therapeutics (ACRS), Lantern Pharma (LTRN), Eton Pharmaceuticals (ETON), Hookipa Pharma (HOOK), Cue Biopharma (CUE), and Carisma Therapeutics (CARM). These companies are all part of the "pharmaceutical preparations" industry.
Leap Therapeutics (NASDAQ:LPTX) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation, community ranking and dividends.
Oncolytics Biotech has lower revenue, but higher earnings than Leap Therapeutics. Oncolytics Biotech is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks.
Leap Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.
30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 11.3% of Leap Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, Leap Therapeutics and Leap Therapeutics both had 1 articles in the media. Oncolytics Biotech's average media sentiment score of 0.39 beat Leap Therapeutics' score of -0.73 indicating that Leap Therapeutics is being referred to more favorably in the media.
Leap Therapeutics presently has a consensus target price of $11.38, suggesting a potential upside of 284.29%. Oncolytics Biotech has a consensus target price of $4.00, suggesting a potential upside of 288.35%. Given Leap Therapeutics' higher probable upside, analysts clearly believe Oncolytics Biotech is more favorable than Leap Therapeutics.
Leap Therapeutics' return on equity of -105.97% beat Oncolytics Biotech's return on equity.
Leap Therapeutics received 137 more outperform votes than Oncolytics Biotech when rated by MarketBeat users. Likewise, 68.65% of users gave Leap Therapeutics an outperform vote while only 68.16% of users gave Oncolytics Biotech an outperform vote.
Summary
Leap Therapeutics beats Oncolytics Biotech on 8 of the 14 factors compared between the two stocks.
Get Oncolytics Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncolytics Biotech Competitors List
Related Companies and Tools
